Neumora Therapeutics announced its Q1 2026 financial results and business updates, highlighting full enrollment in KOASTAL-2 and -3 studies for major depressive disorder with topline data expected in Q2 2026. The company also reported promising Phase 1b results for NMRA-511 in Alzheimer's agitation and plans further data releases and Phase 2 trials in 2026-2027. NMRA-898 and NMRA-215 programs are progressing with data and clinical starts anticipated later in 2026 and early 2027. Neumora holds $147.1 million in cash, supporting operations into Q3 2027, and aims to advance its pipeline with disciplined spending and key upcoming milestones.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
